Ramar Vanajothi, Hemamalini Vedagiri, Mysoon M Al-Ansari, Latifah A Al-Humaid, Premkumar Kumpati. J Biomol Struct Dyn 2022
Times Cited: 1
Times Cited: 1
Times Cited
Times Co-cited
Similarity
Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer.
Takashi Kohno, Takashi Nakaoku, Koji Tsuta, Katsuya Tsuchihara, Shingo Matsumoto, Kiyotaka Yoh, Koichi Goto. Transl Lung Cancer Res 2015
Takashi Kohno, Takashi Nakaoku, Koji Tsuta, Katsuya Tsuchihara, Shingo Matsumoto, Kiyotaka Yoh, Koichi Goto. Transl Lung Cancer Res 2015
100
SwissParam: a fast force field generation tool for small organic molecules.
Vincent Zoete, Michel A Cuendet, Aurélien Grosdidier, Olivier Michielin. J Comput Chem 2011
Vincent Zoete, Michel A Cuendet, Aurélien Grosdidier, Olivier Michielin. J Comput Chem 2011
100
Targeted therapies in non-small cell lung cancer: a focus on ALK/ROS1 tyrosine kinase inhibitors.
Assunta Sgambato, Francesca Casaluce, Paolo Maione, Cesare Gridelli. Expert Rev Anticancer Ther 2018
Assunta Sgambato, Francesca Casaluce, Paolo Maione, Cesare Gridelli. Expert Rev Anticancer Ther 2018
100
ROS1 rearrangements define a unique molecular class of lung cancers.
Kristin Bergethon, Alice T Shaw, Sai-Hong Ignatius Ou, Ryohei Katayama, Christine M Lovly, Nerina T McDonald, Pierre P Massion, Christina Siwak-Tapp, Adriana Gonzalez, Rong Fang,[...]. J Clin Oncol 2012
Kristin Bergethon, Alice T Shaw, Sai-Hong Ignatius Ou, Ryohei Katayama, Christine M Lovly, Nerina T McDonald, Pierre P Massion, Christina Siwak-Tapp, Adriana Gonzalez, Rong Fang,[...]. J Clin Oncol 2012
100
ALK and ROS1 as targeted therapy paradigms and clinical implications to overcome crizotinib resistance.
Mingxiang Ye, Xinxin Zhang, Nan Li, Yong Zhang, Pengyu Jing, Ning Chang, Jianxiong Wu, Xinling Ren, Jian Zhang. Oncotarget 2016
Mingxiang Ye, Xinxin Zhang, Nan Li, Yong Zhang, Pengyu Jing, Ning Chang, Jianxiong Wu, Xinling Ren, Jian Zhang. Oncotarget 2016
100
Pharmacotherapeutics and Molecular Mechanism of Phytochemicals in Alleviating Hormone-Responsive Breast Cancer.
Shailima Rampogu, Chanin Park, Doneti Ravinder, Minky Son, Ayoung Baek, Amir Zeb, Rohit Bavi, Raj Kumar, Gihwan Lee, Shraddha Parate,[...]. Oxid Med Cell Longev 2019
Shailima Rampogu, Chanin Park, Doneti Ravinder, Minky Son, Ayoung Baek, Amir Zeb, Rohit Bavi, Raj Kumar, Gihwan Lee, Shraddha Parate,[...]. Oxid Med Cell Longev 2019
100
Dietary flavonoid intake and lung cancer--a population-based case-control study.
Yan Cui, Hal Morgenstern, Sander Greenland, Donald P Tashkin, Jenny T Mao, Lin Cai, Wendy Cozen, Thomas M Mack, Qing-Yi Lu, Zuo-Feng Zhang. Cancer 2008
Yan Cui, Hal Morgenstern, Sander Greenland, Donald P Tashkin, Jenny T Mao, Lin Cai, Wendy Cozen, Thomas M Mack, Qing-Yi Lu, Zuo-Feng Zhang. Cancer 2008
100
First macrocyclic 3rd-generation ALK inhibitor for treatment of ALK/ROS1 cancer: Clinical and designing strategy update of lorlatinib.
Sulman Basit, Zaman Ashraf, Kwangho Lee, Muhammad Latif. Eur J Med Chem 2017
Sulman Basit, Zaman Ashraf, Kwangho Lee, Muhammad Latif. Eur J Med Chem 2017
100
g_mmpbsa--a GROMACS tool for high-throughput MM-PBSA calculations.
Rashmi Kumari, Rajendra Kumar, Andrew Lynn. J Chem Inf Model 2014
Rashmi Kumari, Rajendra Kumar, Andrew Lynn. J Chem Inf Model 2014
100
Flavonoids potentiated anticancer activity of cisplatin in non-small cell lung cancer cells in vitro by inhibiting histone deacetylases.
Wei Yan, Tracy H Y Wu, Sharon S Y Leung, Kenneth K W To. Life Sci 2020
Wei Yan, Tracy H Y Wu, Sharon S Y Leung, Kenneth K W To. Life Sci 2020
100
Phytochemicals in Cancer Treatment: From Preclinical Studies to Clinical Practice.
Amit S Choudhari, Pallavi C Mandave, Manasi Deshpande, Prabhakar Ranjekar, Om Prakash. Front Pharmacol 2020
Amit S Choudhari, Pallavi C Mandave, Manasi Deshpande, Prabhakar Ranjekar, Om Prakash. Front Pharmacol 2020
100
PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations.
Helen Y Zou, Qiuhua Li, Lars D Engstrom, Melissa West, Vicky Appleman, Katy A Wong, Michele McTigue, Ya-Li Deng, Wei Liu, Alexei Brooun,[...]. Proc Natl Acad Sci U S A 2015
Helen Y Zou, Qiuhua Li, Lars D Engstrom, Melissa West, Vicky Appleman, Katy A Wong, Michele McTigue, Ya-Li Deng, Wei Liu, Alexei Brooun,[...]. Proc Natl Acad Sci U S A 2015
100
Identification of non-resistant ROS-1 inhibitors using structure based pharmacophore analysis.
Disha Pathak, Navriti Chadha, Om Silakari. J Mol Graph Model 2016
Disha Pathak, Navriti Chadha, Om Silakari. J Mol Graph Model 2016
100
Improved protein-ligand docking using GOLD.
Marcel L Verdonk, Jason C Cole, Michael J Hartshorn, Christopher W Murray, Richard D Taylor. Proteins 2003
Marcel L Verdonk, Jason C Cole, Michael J Hartshorn, Christopher W Murray, Richard D Taylor. Proteins 2003
100
Discovery of Entrectinib: A New 3-Aminoindazole As a Potent Anaplastic Lymphoma Kinase (ALK), c-ros Oncogene 1 Kinase (ROS1), and Pan-Tropomyosin Receptor Kinases (Pan-TRKs) inhibitor.
Maria Menichincheri, Elena Ardini, Paola Magnaghi, Nilla Avanzi, Patrizia Banfi, Roberto Bossi, Laura Buffa, Giulia Canevari, Lucio Ceriani, Maristella Colombo,[...]. J Med Chem 2016
Maria Menichincheri, Elena Ardini, Paola Magnaghi, Nilla Avanzi, Patrizia Banfi, Roberto Bossi, Laura Buffa, Giulia Canevari, Lucio Ceriani, Maristella Colombo,[...]. J Med Chem 2016
100
Acquired resistance to crizotinib from a mutation in CD74-ROS1.
Mark M Awad, Ryohei Katayama, Michele McTigue, Wei Liu, Ya-Li Deng, Alexei Brooun, Luc Friboulet, Donghui Huang, Matthew D Falk, Sergei Timofeevski,[...]. N Engl J Med 2013
Mark M Awad, Ryohei Katayama, Michele McTigue, Wei Liu, Ya-Li Deng, Alexei Brooun, Luc Friboulet, Donghui Huang, Matthew D Falk, Sergei Timofeevski,[...]. N Engl J Med 2013
100
Development and validation of a genetic algorithm for flexible docking.
G Jones, P Willett, R C Glen, A R Leach, R Taylor. J Mol Biol 1997
G Jones, P Willett, R C Glen, A R Leach, R Taylor. J Mol Biol 1997
100
Scutellaria Flavonoids Effectively Inhibit the Malignant Phenotypes of Non-small Cell Lung Cancer in an Id1-dependent Manner.
Zhengxiao Zhao, Baojun Liu, Jing Sun, Linwei Lu, Lumei Liu, Jian Qiu, Qiuping Li, Chen Yan, Shan Jiang, Nabijan Mohammadtursun,[...]. Int J Biol Sci 2019
Zhengxiao Zhao, Baojun Liu, Jing Sun, Linwei Lu, Lumei Liu, Jian Qiu, Qiuping Li, Chen Yan, Shan Jiang, Nabijan Mohammadtursun,[...]. Int J Biol Sci 2019
100
Reversal of Multidrug Resistance in Cancer by Multi-Functional Flavonoids.
Qingmei Ye, Kai Liu, Qun Shen, Qingyue Li, Jinghui Hao, Fangxuan Han, Ren-Wang Jiang. Front Oncol 2019
Qingmei Ye, Kai Liu, Qun Shen, Qingyue Li, Jinghui Hao, Fangxuan Han, Ren-Wang Jiang. Front Oncol 2019
100
Pharmacophore-based designing of putative ROS-1 targeting agents for NSCLC.
Disha Pathak, Shalki Choudhary, Pankaj Kumar Singh, Manjinder Singh, Navriti Chadha, Om Silakari. Mol Divers 2021
Disha Pathak, Shalki Choudhary, Pankaj Kumar Singh, Manjinder Singh, Navriti Chadha, Om Silakari. Mol Divers 2021
100
Molecular Simulation Studies on the Binding Selectivity of Type-I Inhibitors in the Complexes with ROS1 versus ALK.
Yuanxin Tian, Yonghuan Yu, Yudong Shen, Hua Wan, Shan Chang, Tingting Zhang, Shanhe Wan, Jiajie Zhang. J Chem Inf Model 2017
Yuanxin Tian, Yonghuan Yu, Yudong Shen, Hua Wan, Shan Chang, Tingting Zhang, Shanhe Wan, Jiajie Zhang. J Chem Inf Model 2017
100
Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship.
Julian R Molina, Ping Yang, Stephen D Cassivi, Steven E Schild, Alex A Adjei. Mayo Clin Proc 2008
Julian R Molina, Ping Yang, Stephen D Cassivi, Steven E Schild, Alex A Adjei. Mayo Clin Proc 2008
100
Protein-ligand-based pharmacophores: generation and utility assessment in computational ligand profiling.
Jamel Meslamani, Jiabo Li, Jon Sutter, Adrian Stevens, Hugues-Olivier Bertrand, Didier Rognan. J Chem Inf Model 2012
Jamel Meslamani, Jiabo Li, Jon Sutter, Adrian Stevens, Hugues-Olivier Bertrand, Didier Rognan. J Chem Inf Model 2012
100
Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.
Monika A Davare, Nadeem A Vellore, Jacob P Wagner, Christopher A Eide, James R Goodman, Alexander Drilon, Michael W Deininger, Thomas O'Hare, Brian J Druker. Proc Natl Acad Sci U S A 2015
Monika A Davare, Nadeem A Vellore, Jacob P Wagner, Christopher A Eide, James R Goodman, Alexander Drilon, Michael W Deininger, Thomas O'Hare, Brian J Druker. Proc Natl Acad Sci U S A 2015
100
Progress in Research on the Role of Flavonoids in Lung Cancer.
Oana Zanoaga, Cornelia Braicu, Ancuta Jurj, Alexandru Rusu, Rares Buiga, Ioana Berindan-Neagoe. Int J Mol Sci 2019
Oana Zanoaga, Cornelia Braicu, Ancuta Jurj, Alexandru Rusu, Rares Buiga, Ioana Berindan-Neagoe. Int J Mol Sci 2019
100
Natural compounds as potential Hsp90 inhibitors for breast cancer-Pharmacophore guided molecular modelling studies.
Shailima Rampogu, Shraddha Parate, Saravanan Parameswaran, Chanin Park, Ayoung Baek, Minky Son, Yohan Park, Seok Ju Park, Keun Woo Lee. Comput Biol Chem 2019
Shailima Rampogu, Shraddha Parate, Saravanan Parameswaran, Chanin Park, Ayoung Baek, Minky Son, Yohan Park, Seok Ju Park, Keun Woo Lee. Comput Biol Chem 2019
100
Tyrosine kinase receptor c-ros-oncogene 1 mediates TWIST-1 regulation of human mesenchymal stem cell lineage commitment.
Esther Camp, Peter J Anderson, Andrew C W Zannettino, Stan Gronthos. Bone 2017
Esther Camp, Peter J Anderson, Andrew C W Zannettino, Stan Gronthos. Bone 2017
100
Recent Developments and Applications of the CHARMM force fields.
Xiao Zhu, Pedro E M Lopes, Alexander D Mackerell. Wiley Interdiscip Rev Comput Mol Sci 2012
Xiao Zhu, Pedro E M Lopes, Alexander D Mackerell. Wiley Interdiscip Rev Comput Mol Sci 2012
100
Focus on ROS1-Positive Non-Small Cell Lung Cancer (NSCLC): Crizotinib, Resistance Mechanisms and the Newer Generation of Targeted Therapies.
Alberto D'Angelo, Navid Sobhani, Robert Chapman, Stefan Bagby, Carlotta Bortoletti, Mirko Traversini, Katia Ferrari, Luca Voltolini, Jacob Darlow, Giandomenico Roviello. Cancers (Basel) 2020
Alberto D'Angelo, Navid Sobhani, Robert Chapman, Stefan Bagby, Carlotta Bortoletti, Mirko Traversini, Katia Ferrari, Luca Voltolini, Jacob Darlow, Giandomenico Roviello. Cancers (Basel) 2020
100
A Novel Crizotinib-Resistant Solvent-Front Mutation Responsive to Cabozantinib Therapy in a Patient with ROS1-Rearranged Lung Cancer.
Alexander Drilon, Romel Somwar, Jacob P Wagner, Nadeem A Vellore, Christopher A Eide, Matthew S Zabriskie, Maria E Arcila, Jaclyn F Hechtman, Lu Wang, Roger S Smith,[...]. Clin Cancer Res 2016
Alexander Drilon, Romel Somwar, Jacob P Wagner, Nadeem A Vellore, Christopher A Eide, Matthew S Zabriskie, Maria E Arcila, Jaclyn F Hechtman, Lu Wang, Roger S Smith,[...]. Clin Cancer Res 2016
100
Pharmacophore-guided fragment-based design of novel mammalian target of rapamycin inhibitors: extra precision docking, fingerprint-based 2D and atom-based 3D-QSAR modelling.
Avinash Kumar, Sudhanshu Rai, Ekta Rathi, Paridhi Agarwal, Suvarna G Kini. J Biomol Struct Dyn 2021
Avinash Kumar, Sudhanshu Rai, Ekta Rathi, Paridhi Agarwal, Suvarna G Kini. J Biomol Struct Dyn 2021
100
Benefit-Risk Summary of Crizotinib for the Treatment of Patients With ROS1 Alteration-Positive, Metastatic Non-Small Cell Lung Cancer.
Dickran Kazandjian, Gideon M Blumenthal, Lola Luo, Kun He, Ingrid Fran, Steven Lemery, Richard Pazdur. Oncologist 2016
Dickran Kazandjian, Gideon M Blumenthal, Lola Luo, Kun He, Ingrid Fran, Steven Lemery, Richard Pazdur. Oncologist 2016
100
Myricetin: versatile plant based flavonoid for cancer treatment by inducing cell cycle arrest and ROS-reliant mitochondria-facilitated apoptosis in A549 lung cancer cells and in silico prediction.
Padmini Rajendran, Uma Maheshwari, Arun Muthukrishnan, Razia Muthuswamy, Krishnan Anand, Balasubramani Ravindran, Premnath Dhanaraj, Balasubramaninan Balamuralikrishnan, Soon Woong Chang, Woo Jin Chung. Mol Cell Biochem 2021
Padmini Rajendran, Uma Maheshwari, Arun Muthukrishnan, Razia Muthuswamy, Krishnan Anand, Balasubramani Ravindran, Premnath Dhanaraj, Balasubramaninan Balamuralikrishnan, Soon Woong Chang, Woo Jin Chung. Mol Cell Biochem 2021
100
TPD52L1-ROS1, a new ROS1 fusion variant in lung adenosquamous cell carcinoma identified by comprehensive genomic profiling.
Viola Weijia Zhu, Daya Upadhyay, Alexa B Schrock, Kyle Gowen, Siraj M Ali, Sai-Hong Ignatius Ou. Lung Cancer 2016
Viola Weijia Zhu, Daya Upadhyay, Alexa B Schrock, Kyle Gowen, Siraj M Ali, Sai-Hong Ignatius Ou. Lung Cancer 2016
100
Pharmacophore modeling in drug discovery and development: an overview.
Santosh A Khedkar, Alpeshkumar K Malde, Evans C Coutinho, Sudha Srivastava. Med Chem 2007
Santosh A Khedkar, Alpeshkumar K Malde, Evans C Coutinho, Sudha Srivastava. Med Chem 2007
100
Total flavonoids suppress lung cancer growth via the COX-2-mediated Wnt/β-catenin signaling pathway.
Lei Han, Shu Fang, Guangtao Li, Minghuan Wang, Renzhi Yu. Oncol Lett 2020
Lei Han, Shu Fang, Guangtao Li, Minghuan Wang, Renzhi Yu. Oncol Lett 2020
100
Design, synthesis, biological evaluation and molecular modeling of novel 2-amino-4-(1-phenylethoxy) pyridine derivatives as potential ROS1 inhibitors.
Yuanxin Tian, Tingting Zhang, Lifan Long, Zhonghuang Li, Shanhe Wan, Guangfa Wang, Yonghuan Yu, Ju Hou, Xiaoyun Wu, Jiajie Zhang. Eur J Med Chem 2018
Yuanxin Tian, Tingting Zhang, Lifan Long, Zhonghuang Li, Shanhe Wan, Guangfa Wang, Yonghuan Yu, Ju Hou, Xiaoyun Wu, Jiajie Zhang. Eur J Med Chem 2018
100
Molecular mechanism and pharmacokinetics of flavonoids in the treatment of resistant EGF receptor-mutated non-small-cell lung cancer: A narrative review.
Xuewen Wang, Bing Chen, Dafen Xu, Zhijun Li, Hao Liu, Zhengjun Huang, Kangping Huang, Xinhua Lin, Hong Yao. Br J Pharmacol 2021
Xuewen Wang, Bing Chen, Dafen Xu, Zhijun Li, Hao Liu, Zhengjun Huang, Kangping Huang, Xinhua Lin, Hong Yao. Br J Pharmacol 2021
100
Novel method for generating structure-based pharmacophores using energetic analysis.
Noeris K Salam, Roberto Nuti, Woody Sherman. J Chem Inf Model 2009
Noeris K Salam, Roberto Nuti, Woody Sherman. J Chem Inf Model 2009
100
A Novel Flavonoid Kushenol Z from Sophora flavescens Mediates mTOR Pathway by Inhibiting Phosphodiesterase and Akt Activity to Induce Apoptosis in Non-Small-Cell Lung Cancer Cells.
Hao Chen, Jie Yang, Ji Hao, Yibing Lv, Lu Chen, Qinxiong Lin, Jingquan Yuan, Xinzhou Yang. Molecules 2019
Hao Chen, Jie Yang, Ji Hao, Yibing Lv, Lu Chen, Qinxiong Lin, Jingquan Yuan, Xinzhou Yang. Molecules 2019
100
Non-Small Cell Lung Cancer from Genomics to Therapeutics: A Framework for Community Practice Integration to Arrive at Personalized Therapy Strategies.
Swapnil Rajurkar, Isa Mambetsariev, Rebecca Pharaon, Benjamin Leach, TingTing Tan, Prakash Kulkarni, Ravi Salgia. J Clin Med 2020
Swapnil Rajurkar, Isa Mambetsariev, Rebecca Pharaon, Benjamin Leach, TingTing Tan, Prakash Kulkarni, Ravi Salgia. J Clin Med 2020
100
Identification of mitoxantrone as a new inhibitor of ROS1 fusion protein in non-small cell lung cancer cells.
Lian-Xiang Luo, Xing-Xing Fan, Ying Li, Xia Peng, Yin-Chun Ji, Wendy Wen-Luan Hsiao, Liang Liu, Elaine Lai-Han Leung, Xiao-Jun Yao. Medchemcomm 2017
Lian-Xiang Luo, Xing-Xing Fan, Ying Li, Xia Peng, Yin-Chun Ji, Wendy Wen-Luan Hsiao, Liang Liu, Elaine Lai-Han Leung, Xiao-Jun Yao. Medchemcomm 2017
100
New features that improve the pharmacophore tools from Accelrys.
Jon Sutter, Jiabo Li, Allister J Maynard, Anne Goupil, Tien Luu, Katalin Nadassy. Curr Comput Aided Drug Des 2011
Jon Sutter, Jiabo Li, Allister J Maynard, Anne Goupil, Tien Luu, Katalin Nadassy. Curr Comput Aided Drug Des 2011
100
Investigation of novel chemical scaffolds targeting prolyl oligopeptidase for neurological therapeutics.
Raj Kumar, Saravanan Parameswaran, Rohit Bavi, Ayoung Baek, Minky Son, Shailima Rampogu, Chanin Park, Gihwan Lee, Amir Zeb, Shraddha Parate,[...]. J Mol Graph Model 2019
Raj Kumar, Saravanan Parameswaran, Rohit Bavi, Ayoung Baek, Minky Son, Shailima Rampogu, Chanin Park, Gihwan Lee, Amir Zeb, Shraddha Parate,[...]. J Mol Graph Model 2019
100
Marine-Derived Natural Products as ATP-Competitive mTOR Kinase Inhibitors for Cancer Therapeutics.
Shraddha Parate, Vikas Kumar, Gihwan Lee, Shailima Rampogu, Jong Chan Hong, Keun Woo Lee. Pharmaceuticals (Basel) 2021
Shraddha Parate, Vikas Kumar, Gihwan Lee, Shailima Rampogu, Jong Chan Hong, Keun Woo Lee. Pharmaceuticals (Basel) 2021
100
Testing for ROS1 in non-small cell lung cancer: a review with recommendations.
Lukas Bubendorf, Reinhard Büttner, Fouad Al-Dayel, Manfred Dietel, Göran Elmberger, Keith Kerr, Fernando López-Ríos, Antonio Marchetti, Büge Öz, Patrick Pauwels,[...]. Virchows Arch 2016
Lukas Bubendorf, Reinhard Büttner, Fouad Al-Dayel, Manfred Dietel, Göran Elmberger, Keith Kerr, Fernando López-Ríos, Antonio Marchetti, Büge Öz, Patrick Pauwels,[...]. Virchows Arch 2016
100
ALK inhibitors for non-small cell lung cancer: A systematic review and network meta-analysis.
Jesse Elliott, Zemin Bai, Shu-Ching Hsieh, Shannon E Kelly, Li Chen, Becky Skidmore, Said Yousef, Carine Zheng, David J Stewart, George A Wells. PLoS One 2020
Jesse Elliott, Zemin Bai, Shu-Ching Hsieh, Shannon E Kelly, Li Chen, Becky Skidmore, Said Yousef, Carine Zheng, David J Stewart, George A Wells. PLoS One 2020
100
Foretinib is a potent inhibitor of oncogenic ROS1 fusion proteins.
Monika A Davare, Anna Saborowski, Christopher A Eide, Cristina Tognon, Rebecca L Smith, Johannes Elferich, Anupriya Agarwal, Jeffrey W Tyner, Ujwal P Shinde, Scott W Lowe,[...]. Proc Natl Acad Sci U S A 2013
Monika A Davare, Anna Saborowski, Christopher A Eide, Cristina Tognon, Rebecca L Smith, Johannes Elferich, Anupriya Agarwal, Jeffrey W Tyner, Ujwal P Shinde, Scott W Lowe,[...]. Proc Natl Acad Sci U S A 2013
100
Detection of ROS1 gene rearrangement in lung adenocarcinoma: comparison of IHC, FISH and real-time RT-PCR.
Ling Shan, Fang Lian, Lei Guo, Tian Qiu, Yun Ling, Jianming Ying, Dongmei Lin. PLoS One 2015
Ling Shan, Fang Lian, Lei Guo, Tian Qiu, Yun Ling, Jianming Ying, Dongmei Lin. PLoS One 2015
100
Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.